Why did the G-BA assess Trimbow now?
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Trimbow was launched onto the German market in 2017. So why did the G-BA assess its benefit now? You likely know that
At the time of launch in the German market, pharmaceutical companies are free to set the price for their product with a
The antiviral drug remdesivir (brand name: Veklury) has been the first drug targeting COVID-19, which has undergone an early benefit assessment. It
If the G-BA concludes its early benefit assessment with “No additional benefit (proven)” and the product falls into a reference price group,